Life Sciences Weekly
Resources
Browse and filter sharp, essential coverage across every life sciences topic that matters.
Life Sciences Weekly
Browse and filter sharp, essential coverage across every life sciences topic that matters.
A sweeping meta-analysis of two decades of clinical data asks whether the precision medicine premium has permanently compressed, and what that means for portfolio construction in 2026.
The cell and gene therapy pipeline has never been larger, with over 1,000 active programmes globally. Yet the gap between clinical promise and commercial execution is widening.
Quantitative analysis of 900 Phase III programmes reveals that avoidable trial design flaws account for nearly 40% of late-stage failures, creating a systemic drag on industry R&D productivity.
After two years of suppressed deal flow, the biotech acquisition pipeline is opening up. Dealmakers and corporate development teams share what the next 18 months are likely to look like, and which therapeutic areas will lead.
The technology that powered COVID-19 vaccines is now being applied to oncology, rare disease, and infectious disease programmes at an unprecedented pace.
A wave of blockbuster biologics is losing patent protection over the next three years. New data on biosimilar penetration rates reveals which therapeutic categories face the steepest revenue erosion.
Life sciences leaders need a framework for navigating the FDA's evolving approval posture. Regulatory strategists break down three scenarios and the pipeline planning implications of each.
The ripple effects of GLP-1 demand are forcing life sciences supply teams to rebuild cost models from the ground up. Here is the analytical framework leading CSOs are using to stress-test their manufacturing assumptions.
Stubborn pockets of payer resistance are persisting even as biosimilar penetration increases. What the data reveals about the structural shifts driving this divergence, and how long it can last.
Digital-native health platforms have captured $28 billion in life sciences revenue in three years. We look at which legacy pharma institutions are mounting a credible competitive response, and which are losing ground.
AI-powered trial design and patient recruitment tools are delivering measurable results. We analysed 80 trials and found that programmes using adaptive AI protocols completed Phase II a median of 14 months faster.
Regulators are increasingly accepting real-world evidence to support approval and label expansion decisions. Sponsors who understand the new evidentiary standards will have a significant competitive advantage.
The FDA's updated requirements are now in effect. Regulatory and legal teams walk through the six areas most likely to require new data infrastructure, revised submissions, and external audit support.
The IRA's Medicare drug price negotiation framework is now live. A frank assessment of where most companies stand, which gaps are most urgent to close, and what payers are likely to scrutinise first.
Three years on, we assess which companies have genuinely rebuilt resilience versus which have made only cosmetic changes, and what a durable supply chain model actually requires.
As AI reshapes every function of the enterprise, chief scientific officers face a defining moment: transform the R&D model or risk being outpaced by faster-moving competitors.
New research maps the capabilities separating the CSOs who are driving strategic transformation from those still managing pipelines, and the specific behaviours that define the difference.
Life sciences teams are losing top scientists to better-paying roles in tech and consulting at an accelerating rate. Leaders who have solved the retention problem share what actually works.
Try a different search term or topic filter.